Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
IDEXX Laboratories Inc (IDXX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
05/27/2025: IDXX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -5.29% | Avg. Invested days 23 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 05/27/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 40.34B USD | Price to earnings Ratio 46.31 | 1Y Target Price 501.62 |
Price to earnings Ratio 46.31 | 1Y Target Price 501.62 | ||
Volume (30-day avg) 807803 | Beta 1.52 | 52 Weeks Range 356.14 - 530.60 | Updated Date 05/27/2025 |
52 Weeks Range 356.14 - 530.60 | Updated Date 05/27/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 10.83 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-05-01 | When Before Market | Estimate 2.8444 | Actual 2.96 |
Profitability
Profit Margin 22.76% | Operating Margin (TTM) 31.7% |
Management Effectiveness
Return on Assets (TTM) 22.98% | Return on Equity (TTM) 59.33% |
Valuation
Trailing PE 46.31 | Forward PE 41.67 | Enterprise Value 41232609909 | Price to Sales(TTM) 10.26 |
Enterprise Value 41232609909 | Price to Sales(TTM) 10.26 | ||
Enterprise Value to Revenue 10.49 | Enterprise Value to EBITDA 31.98 | Shares Outstanding 80421904 | Shares Floating 79523604 |
Shares Outstanding 80421904 | Shares Floating 79523604 | ||
Percent Insiders 0.67 | Percent Institutions 96.88 |
Analyst Ratings
Rating 3.62 | Target Price 497.46 | Buy 3 | Strong Buy 3 |
Buy 3 | Strong Buy 3 | ||
Hold 6 | Sell 1 | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
IDEXX Laboratories Inc
Company Overview
History and Background
IDEXX Laboratories, Inc. was founded in 1983 and is headquartered in Westbrook, Maine. It initially focused on developing and marketing diagnostic tests for livestock and expanded into companion animal diagnostics. Over time, IDEXX has grown through organic development and acquisitions, becoming a global leader in pet healthcare innovation.
Core Business Areas
- Companion Animal Group (CAG) Diagnostics: This segment focuses on diagnostic products and services for companion animals, including in-clinic analyzers, reference laboratory services, rapid assay tests, and veterinary software. This segment contributes the most significant portion of IDEXX's revenue.
- Water Quality Products: This segment develops and manufactures tests for detecting microbiological and chemical contaminants in water. These tests are used in municipal water supplies, private wells, and recreational water sources.
- Livestock, Poultry and Dairy (LPD): This segment focuses on diagnostics and information management solutions for livestock, poultry and dairy, improving animal health and productivity.
- Opti Medical Systems: Develops and manufactures blood gas analyzers for use in human medical critical care settings.
Leadership and Structure
IDEXX is led by Jay Mazelsky (President and CEO). The company has a standard corporate structure with various executive leadership roles overseeing different business segments and functions.
Top Products and Market Share
Key Offerings
- VetLabu00ae Suite: This is a comprehensive in-clinic diagnostic system for veterinary practices, including chemistry, hematology, immunoassay, and urine analyzers. Includes market share data with ~70% market share of in-clinic diagnostic analyzers. Competitors include Zoetis, Heska, and Abaxis (now part of Zoetis).
- Reference Laboratories: IDEXX operates a network of reference laboratories that provide a wide range of diagnostic testing services to veterinarians. Competitors include Antech Diagnostics (Mars, Incorporated) and VCA Antech (also part of Mars, Incorporated).
- SNAPu00ae Tests: These are rapid assay tests for common companion animal diseases, providing quick results in the veterinary clinic. Competitors include Zoetis and Heska.
- Water Testing: IDEXX provides tests for drinking water, wastewater, and environmental water, used globally to ensure water safety.
Market Dynamics
Industry Overview
The animal health diagnostics market is experiencing strong growth, driven by increasing pet ownership, rising veterinary spending, and advancements in diagnostic technology. Aging populations in developed countries also contribute to growth due to a higher prevalence of age-related diseases in pets. The water quality testing market is driven by increasing regulation and concerns about water safety and availability.
Positioning
IDEXX is a leading player in the animal health diagnostics market, known for its innovative products, high-quality testing services, and strong brand reputation. The company has a competitive advantage due to its large installed base of analyzers, extensive reference laboratory network, and strong customer relationships.
Total Addressable Market (TAM)
The global animal health diagnostics market is estimated to be over $8 billion and continues to grow, with projections indicating further expansion. The global water quality testing market is also substantial. IDEXX is well-positioned to capitalize on this TAM with its comprehensive product portfolio and global reach.
Upturn SWOT Analysis
Strengths
- Strong brand reputation
- Large installed base of diagnostic equipment
- Extensive reference laboratory network
- Innovative product development
- Global presence
Weaknesses
- High product prices
- Dependence on veterinary spending
- Exposure to regulatory changes
- Reliance on distributors for some markets
Opportunities
- Expanding into emerging markets
- Developing new diagnostic tests and technologies
- Acquiring smaller diagnostic companies
- Capitalizing on the growing pet insurance market
- Increase the water testing business
Threats
- Competition from other diagnostic companies
- Economic downturns affecting veterinary spending
- Changes in regulations governing animal health and water quality
- Emergence of new infectious diseases
Competitors and Market Share
Key Competitors
- ZTS
- VET
- BIO
Competitive Landscape
IDEXX holds a competitive advantage through its comprehensive VetLab suite and reference lab network. While competitors like Zoetis have a strong presence, IDEXX maintains its innovative product portfolio and client satisfaction.
Major Acquisitions
ezyVet
- Year: 2021
- Acquisition Price (USD millions): 207
- Strategic Rationale: Expanded IDEXX's veterinary software solutions and integrated workflows for veterinary practices.
Growth Trajectory and Initiatives
Historical Growth: IDEXX has demonstrated strong historical growth, driven by organic expansion and acquisitions.
Future Projections: Analysts project continued revenue and earnings growth for IDEXX, driven by increasing demand for animal health diagnostics and water quality testing. This forecast can change so it is important to check current reports.
Recent Initiatives: Recent initiatives include expanding the reference laboratory network, launching new diagnostic tests, and acquiring companies in related markets.
Summary
IDEXX Laboratories is a strong company with a leading position in the animal health diagnostics market, supported by its innovative product portfolio and global presence. Its consistent financial performance and growth prospects make it a solid player, but it needs to watch out for competition and regulatory changes. Its ongoing commitment to research and development, along with strategic acquisitions, fuels further expansion and reinforces its position. Investors should continue to monitor these areas to ensure IDEXX maintains its leading role.
Similar Companies
BIO
Bio-Rad Laboratories Inc
BIO
Bio-Rad Laboratories Inc
DGX
Quest Diagnostics Incorporated
DGX
Quest Diagnostics Incorporated
LH
Laboratory Corporation of America Holdings
LH
Laboratory Corporation of America Holdings
VET
Vermilion Energy Inc.
VET
Vermilion Energy Inc.
ZTS
Zoetis Inc
ZTS
Zoetis Inc
Sources and Disclaimers
Data Sources:
- IDEXX Laboratories Inc. Investor Relations
- Financial News Outlets
- Market Research Reports
- Company SEC Filings
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market data and analyst estimates are subject to change. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About IDEXX Laboratories Inc
Exchange NASDAQ | Headquaters Westbrook, ME, United States | ||
IPO Launch date 1991-06-21 | President, CEO & Director Mr. Jonathan J. Mazelsky | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 11000 | Website https://www.idexx.com |
Full time employees 11000 | Website https://www.idexx.com | ||
IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It offers in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology, and coagulation analyzers; and SNAP rapid assays test kits. The company also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services, including radiology, dental radiography, cardiology, internal medicine, and ultrasound consulting; Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, Quanti-Tray products, and Tecta system instruments; and veterinary software and services for independent veterinary clinics and corporate groups. In addition, it offers diagnostic tests, services, and related instrumentation for manage the health status of livestock and poultry; human medical diagnostic products and services; and VetConnect PLUS, a cloud-based technology that enables veterinarians to access and analyze patients, as well as operates VetLab Station. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
